CN113164477A - C-jun-n-末端激酶的吡唑并吡啶抑制剂及其用途 - Google Patents

C-jun-n-末端激酶的吡唑并吡啶抑制剂及其用途 Download PDF

Info

Publication number
CN113164477A
CN113164477A CN201980080949.8A CN201980080949A CN113164477A CN 113164477 A CN113164477 A CN 113164477A CN 201980080949 A CN201980080949 A CN 201980080949A CN 113164477 A CN113164477 A CN 113164477A
Authority
CN
China
Prior art keywords
optionally substituted
certain embodiments
compound
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980080949.8A
Other languages
English (en)
Chinese (zh)
Inventor
N.S.格雷
T.张
Y.刘
Y.高
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of CN113164477A publication Critical patent/CN113164477A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201980080949.8A 2018-12-14 2019-12-13 C-jun-n-末端激酶的吡唑并吡啶抑制剂及其用途 Pending CN113164477A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862780066P 2018-12-14 2018-12-14
US62/780,066 2018-12-14
PCT/US2019/066201 WO2020123925A1 (en) 2018-12-14 2019-12-13 Pyrazolopyridine inhibitors of c-jun-n-terminal kinases and uses thereof

Publications (1)

Publication Number Publication Date
CN113164477A true CN113164477A (zh) 2021-07-23

Family

ID=71077020

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980080949.8A Pending CN113164477A (zh) 2018-12-14 2019-12-13 C-jun-n-末端激酶的吡唑并吡啶抑制剂及其用途

Country Status (7)

Country Link
US (1) US20220073512A1 (https=)
EP (1) EP3893879A4 (https=)
JP (1) JP7642540B2 (https=)
CN (1) CN113164477A (https=)
AU (1) AU2019395255B2 (https=)
CA (1) CA3115126A1 (https=)
WO (1) WO2020123925A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120661695A (zh) * 2025-06-20 2025-09-19 山东大学第二医院 联合上调snrk基因与gsk3b基因表达水平在制备抗非小细胞肺癌药物中的应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011090738A2 (en) 2009-12-29 2011-07-28 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
JP6854762B2 (ja) 2014-12-23 2021-04-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
USRE50776E1 (en) 2015-03-27 2026-02-03 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
AU2017363307B2 (en) * 2016-11-22 2021-07-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof
US12281126B2 (en) 2018-12-28 2025-04-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
CA3147422A1 (en) * 2019-07-17 2021-01-21 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160264551A1 (en) * 2013-10-18 2016-09-15 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007123892A2 (en) 2006-04-17 2007-11-01 Arqule Inc. Raf inhibitors and their uses
WO2010144416A1 (en) 2009-06-08 2010-12-16 Gaeta Federico C A SUBSTITUTED PYRAZOLO [1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY
BR112013011520A2 (pt) * 2010-11-19 2019-09-24 Hoffmann La Roche pirazolo piridinas e pirazolo piridinas e seu uso como inibidores de tyk2
US9382239B2 (en) 2011-11-17 2016-07-05 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
TWI621618B (zh) * 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
EP3057956B1 (en) * 2013-10-18 2021-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160264551A1 (en) * 2013-10-18 2016-09-15 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120661695A (zh) * 2025-06-20 2025-09-19 山东大学第二医院 联合上调snrk基因与gsk3b基因表达水平在制备抗非小细胞肺癌药物中的应用

Also Published As

Publication number Publication date
AU2019395255A1 (en) 2021-05-06
JP2022513846A (ja) 2022-02-09
US20220073512A1 (en) 2022-03-10
WO2020123925A1 (en) 2020-06-18
AU2019395255B2 (en) 2025-02-27
EP3893879A4 (en) 2022-08-17
CA3115126A1 (en) 2020-06-18
JP7642540B2 (ja) 2025-03-10
EP3893879A1 (en) 2021-10-20

Similar Documents

Publication Publication Date Title
CN113164477A (zh) C-jun-n-末端激酶的吡唑并吡啶抑制剂及其用途
JP7200282B2 (ja) サイクリン依存性キナーゼの阻害剤
US11932625B2 (en) Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof
JP7308146B2 (ja) インターロイキン１受容体関連キナーゼの阻害剤およびその使用
CN105073768A (zh) Ras抑制剂及其用途
WO2016210296A1 (en) 4,6-pyrimidinylene derivatives and uses thereof
CN112367991A (zh) Taire家族激酶抑制剂及其用途
JP2025098013A (ja) がん幹細胞を標的化するがん治療
JP7675070B2 (ja) 治療、特にｍｙｄ８８変異疾患における使用のためのｈｃｋ阻害剤としてのピラゾロピリミジン誘導体
US12612368B2 (en) Cancer treatments targeting cancer stem cells
HK1256417A1 (zh) 氰基噻吩并三唑并二氮杂环庚三烯及其用途
EP3860597A1 (en) Pi3k inhibitors and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Country or region after: U.S.A.

Address after: Massachusetts, USA

Applicant after: Dana Faber Cancer Institute

Address before: Massachusetts, USA

Applicant before: DANA-FARBER CANCER INSTITUTE, Inc.

Country or region before: U.S.A.

CB02 Change of applicant information
RJ01 Rejection of invention patent application after publication

Application publication date: 20210723

RJ01 Rejection of invention patent application after publication